Rahimi Roja, Nikfar Shekoufeh, Rahimi Fatemeh, Elahi Behzad, Derakhshani Saeed, Vafaie Mohammad, Abdollahi Mohammad
Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Dig Dis Sci. 2008 Sep;53(9):2524-31. doi: 10.1007/s10620-007-0171-0. Epub 2008 Feb 14.
To evaluate whether probiotics maintain remission in patients with Crohn's disease (CD).
A meta-analysis of controlled clinical trials.
PUBMED and Cochrane Central Register of Controlled Trials were searched for clinical trial studies investigated the efficacy of probiotics for the maintenance of remission in Crohn's disease. Clinical relapse and endoscopic relapse were the key outcomes of interest. Data were searched within the time period of 1966 through May 2007.
Eight randomized placebo-controlled clinical trials met our criteria and were included in the analysis. Seven determined clinical relapse and three evaluated endoscopic relapse among patients with CD received probiotics for maintenance of remission. Pooling of seven trials for the outcome of clinical relapse yielded an odds ratio of 0.92 (95% confidence interval of 0.52-1.62, P = 0.8853), a nonsignificant odds ratio. The odds ratio for three studies for the outcome of endoscopic relapse was 0.97 (95% confidence interval of 0.54-1.78, P = 0.93), a nonsignificant odds ratio.
This meta-analysis fails to demonstrate the efficacy of probiotics in maintaining remission and preventing clinical and endoscopic recurrence in CD. It is suggested to use probiotic preparations containing a mixture of lactobacillus with E. coli or Saccharomyces.
评估益生菌能否维持克罗恩病（CD）患者的病情缓解状态。
对对照临床试验进行的一项荟萃分析。
检索了PUBMED和Cochrane对照试验中心注册库，查找研究益生菌对维持克罗恩病病情缓解疗效的临床试验研究。临床复发和内镜复发是主要关注的结果。在1966年至2007年5月期间检索数据。
八项随机安慰剂对照临床试验符合我们的标准并纳入分析。七项试验确定了接受益生菌维持病情缓解的CD患者中的临床复发情况，三项试验评估了内镜复发情况。对七项关于临床复发结果的试验进行汇总，得出优势比为0.92（95%置信区间为0.52 - 1.62，P = 0.8853），这是一个无统计学意义的优势比。三项关于内镜复发结果的研究的优势比为0.97（95%置信区间为0.54 - 1.78，P = 0.93），也是一个无统计学意义的优势比。
这项荟萃分析未能证明益生菌在维持CD病情缓解及预防临床和内镜复发方面的疗效。建议使用含有乳酸杆菌与大肠杆菌或酿酒酵母混合物的益生菌制剂。
